Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine, Cyclophosphamide and Etoposide for MRD Positive Acute Leukemia
NCT01677949Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2013
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients Unable to Proceed to Transplantation. Planned start Dec 2013; status: withdrawn.
02
Drugs
clofarabine
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01677949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677949.